Overview

A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

Status:
COMPLETED
Trial end date:
2025-02-07
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare pharmacokinetic exposures following intravenous and subcutaneous administration of Risankizumab.
Phase:
PHASE1
Details
Lead Sponsor:
AbbVie
Treatments:
risankizumab